The Xanthine Dehydrogenase/Oxidase pipeline drugs market research report outlays comprehensive information on the Xanthine Dehydrogenase/Oxidase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Xanthine Dehydrogenase/Oxidase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Musculoskeletal Disorders, Genito Urinary System, and Central Nervous System which include the indications Hyperuricemia, Mitochondrial Diseases, Gouty Arthritis (Gout), Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Xanthine Dehydrogenase/Oxidase targeted therapeutics development with respective active and dormant or discontinued products.
The Xanthine Dehydrogenase/Oxidase pipeline targets constitutes close to 18 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 5, 5, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 1 molecule.
Xanthine Dehydrogenase/Oxidase overview
Xanthine dehydrogenase (XDH) is a key enzyme in purine degradation. It catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid.
For a complete picture of Xanthine Dehydrogenase/Oxidase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
